Skip to content

Net Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.24B-52.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
Glaukos logo
GlaukosGKOS
-$19.78M-9.0%
AbbVie logo
AbbVieABBV
$695M-46.0%
Bausch + Lomb logo
Bausch + LombBLCO
-$71M+66.5%
HRO
HarrowHROW
-$27.6M-55.2%

Segments

By segment

See full
Reporting Segment-$13.82M-56.6%

Other financials

Income statement

See full
Operating income-$15.4M-108%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's net income?
Schering-Plough (SGP) reported net income of -$13.82M in Q1 2026.
How has Schering-Plough's net income changed year-over-year?
Schering-Plough's net income decreased by 56.6% year-over-year, from -$8.82M to -$13.82M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.